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Abstract
Background: Cardiovascular disease (CAD) responsible and nonalcoholic fatty liver disease (NAFLD) are both
metabolic diseases, and they are mostly influenced by genetic factors. The aim of our study is to evaluate the relationship
between angiotensin II type-1 receptor (AGTR1) gene rs3772622 polymorphisms and the risk of developing coronary artery
disease (CAD) in Chinese patients with NAFLD.
Methods: Genotype for AGTR1 rs3772622 in 574 NAFLD patients with CAD or 589 NAFLD patients without CAD, 332 CAD
patients exclude NAFLD and 338 health control subjects were determined by sequencing and polymerase chain reaction
analysis. Relevant statistical methods were employed to analyze the genotypes, alleles and the clinical date. Inter-group
differences and associations were assessed statistically using t-tests and Chi square and logistic analyses. The relative risk of
AGTR1 rs3772622 for NAFLD was estimated by logistic regression analysis.
Results: No significant difference in genotype and allele frequency of AGTR1 rs3772622 was found between the NAFLD
without CAD population and the controls (P > 0.05). However, makeable difference was found when compared the CAD
in patients with NAFLD and CAD free NAFLD patients (P < 0.001 OR = 2.09). Similarly, significant difference was found in
AGTR1 rs3772622 genotype distribution between the groups of CAD patients and control (P = 0.046 OR = 1.71).
Conclusions: AGTR1 rs3772622 gene polymorphism was not associated with the risk of NAFLD, but could increase the risk
of NAFLD patients suffering from CAD in the Chinese Han population. Deeply mechanisms underlying the association
between AGTR1 rs3772622 gene polymorphism and the risk of CAD in NAFLD patients need more research.
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Background
Nonalcoholic fatty liver disease (NAFLD) influenced by
the incidence of Obesity has become one of the most
common chronic liver disease and a primary health issue
[1]. NAFLD is a metabolic disease without obvious alcohol
intake, because of the abnormal metabolism making fat
accumulated in the liver. On behalf of a spectrum of
disease, NAFLD range from simple steatosis to steatohe-
patitis, and finally lead to cirrhosis [2, 3]. NAFLD can
increased the risk of all-cause mortality, contributed by
liver related deaths as well as non-liver related causes such
as malignancy, diabetes and coronary artery disease
(CAD) [4]. Epidemiological studies performed in United
States and Japan showed that NAFLD can increased the
risk of cardiovascular disease (CVD) and is a predictor of
CVD independent of the presence of other metabolic
syndrome risk factors, such as hypertension, diabetes,
dyslipidaemia, insulin resistance (IR) and obesity [5, 6].
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Angiotensin II type 1 receptor (AGTR1) gene has been
implicated with susceptibility to NAFLD and was reported
playing a fibrogenic role in NAFLD. Polymorphism of
AGTR1 rs3772622 was reported to be associated with
increased fibrosis score [7]. Furthermore, AGTR1 is an
important receptor that controlling blood pressure and
regulating cardiovascular homeostasis. It was reported
that AGTR1 gene (A1166C) polymorphism was associated
with hypertension and atherosclerotic stroke [8–11]. It
was reasonable to speculate that AGTR1 may be one of
the candidate genes in the susceptibility for NAFLD
patients with CAD. However, the role of AGTR1
rs3772622 in atherosclerosis has not been elucidated.
This is the first report to investigate the association




Our study was confirmed by the Ethical Committee of
Qingdao Municipal Hospital (Qingdao, China), the refer-
ence number: 2015–01. And we prepared a written
informed consent form for the participants to confirm
that they were willing to participate. This study was car-
ried out on the basis of the principles of the Declaration
of Helsinki [12].
Study subjects
The controls were recruited from the Departments of
Gastroenterology and Cardiology of Qingdao Municipal
Hospital. All groups of participant were of Northern
Han Chinese origin. NAFLD patients were diagnosed by
B-type ultrasonography, The diagnosis of NAFLD was
according to the standard clinical evaluation [13]. CAD
was diagnosed by a percutaneous coronary angiogram,
and the final diagnosis was determined by two skilled
interventional cardiologists, diagnostic criteria for CAD
is that not less than 50 % stenosis in at least one of the
coronary arteries. The individuals in control group were
confirmed as being normal by echocardiography and
laboratory examinations at the identical hospital. Sub-
jects should be excluded other liver diseases, such as
nonalcoholic fatty hepatitis (NASH), the drug-induced
liver disease, autoimmune liver disease, viral hepatitis, and
the Weekly drinking > 140 g, other diseases such as car-
diac disorders, concurrent major renal, infectious disease,
diabetes mellitus, and malignant disease, and a history of
medication. Study questionnaire was used to get the basic
clinic pathological information (name, age, etc.).
To test our hypothesis, we finally selected a total of
1163 unrelated adult Chinese NAFLD patients of both
genders [574 patients with CAD (292 females, 282
males, mean age 43.81 ± 7.58) and 589 patients without
CAD (301 females, 288 males, mean age 45.06 ± 8.77)].
332 unrelated adult Chinese CAD patients without
NAFLD of both genders (168 females, 164 males, mean
age 46.45 ± 9.68), and 338 health control of both genders
(173 females, 165 males, mean age 43.85 ± 8.79). All sub-
jects were of Northern Han Chinese origin, as described
previously.
Clinical and laboratory assessments
Each of the subjects was fasted for 12 h before
examination. For biochemical analyses, blood samples
of all participants were determined for Triglyceride
(TG), serum levels of total cholesterol (TC), high-
density lipoprotein (HDL), low-density lipoprotein
(LDL), alanine aminotransferase (ALT), and aspartate
aminotransferase (AST), and gamma-glutamyl trans-
peptidase (GGT). The biochemical tests were ana-
lyzed by applying an automatic biochemistry analyzer
(Hitachi P7600). Body weight and height were
measured for calculate body mass index (BMI).
According to a standard protocol of the 3-day base-
line observation on each morning, three BP measure-
ments can be obtained. The men who have a systolic
BP ≧ 140 mmHg and/or diastolic BP ≧ 90 mmHg or
use of antihypertensive medication can be diagnosed
as hypertension.
Genotyping
Simples of peripheral blood were collected and genomic
DNA was extracted by using the Genomic DNA Purifica-
tion Kit (CWBIO, China), then stored at −20 °C until use.
The AGTR1 SNP was genotyped using PCR analysis with
the following primers for AGTR1 rs3772622 polymorph-
ism: 5′ - CAGGAGCTCTGAGAGGAATGTTCAG - 3′
and 5′-TGGCAGATCAGCTGGGTTCATT-3′. The amp-
lified reaction system and the PCR amplification profile
progressed as previously described [14].
Statistical analysis
SPSS statistical software, version 20.0 (SPSS, Chicago, IL,
USA) can be used to analyze data. Inspection level a = 0.05.
Firstly, the quantitative data in the indexes were tested
by t test, and the results were represented by the form
of mean ± standard deviation (S.D.). Through counting
DNA sequencing data, the genotype and allele frequen-
cies can be estimated. The distinctions between studied
groups were analyzed by Pearson’s χ2 test. Then, logistic
regression analysis was used to measure the strength of
the association between AGTR1 rs3772622 polymorph-
ism and CAD, and it evaluated by the OR (95 % CI). At
last, by comparing the OR values of the two groups
with/without NAFLD, we can find the association
between AGTR1 gene polymorphisms and coronary
artery disease in patients with nonalcoholic fatty liver
disease.
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Results
Sample basic information
Table 1 presented the basic characteristics of this study
population. There was no statistical significance in gender
and age in each group (all p > 0.05). While, compared to
the health control group, groups of NAFLD patients, with
or without CAD (CAD+ NAFLD/CAD- NAFLD), and
CAD patients without NAFLD (NAFLD- CAD) had
increased serum ALT, AST, TG, TC, and LDL levels, BMI
index, while the HDL levels decreased. (p1,2,3 < 0.001).
Importantly, CAD+ NAFLD group patients had higher
TG, TC, and LDL levels and lower HDL level than
CAD- NAFLD group patients (p4 < 0.001).
AGTR1 rs3772622 genotype and allele distribution
The genotype and allele distribution were showed in
Table 2, it indicated that there was no significant differ-
ence between CAD- NAFLD patients and control group
(p > 0.05). As shown in Table 3, there was significant
difference in genotypic and allelic distributions between
the NAFLD patients with or without CAD (OR: 2.09,
95 % CI: 1.49-2.95, P < 0.001; OR: 1.83, 95 % CI: 1.39-
2.41, P < 0.001 respectively). Furthermore, a consider-
able significant difference of genotype distribution were
observed between CAD patients without NAFLD and
health control people (OR: 1.71, 95 % CI: 1.002-2.860,
P = 0.046), While there’s no significant difference of
alleles distribution were observed from the above
groups (OR: 1.04, 95 % CI: 0.77-1.41, P = 0.80).
Discussion and conclusions
In China, NAFLD has become the most common form
of liver disease, and it recognized as the second largest
chronic liver disease [15–18]. As a hepatic manifestation
of the metabolic syndrome, we can suppose that NAFLD
may promote the development of atherosclerosis [5, 6].
Some reports demonstrated that because of the promot-
ing effect on CVD, NAFLD patients were at high risk of
death [8, 10]. Nowadays many epidemiological and clin-
ical studies focus on the association between NAFLD
and CAD [19–24]. Several studies have reported that
NAFLD is a strong risk factor for CAD [25, 26]. A study
demonstrates that NAFLD is an independent risk factor
for angiographically in Koreans population, and also
demonstrate that in Asians NAFLD can independently
influence the progression to CAD [26].
AGTR1 is the receptor of Angiotensin II (AngII) [27],
AngII as a potent vasopressor hormone and a main
regulator of aldosterone secretion plays an important
role in blood pressure control and also related to the
pathogenesis of coronary diseases [11, 28–31]. The main
effect of AGTR1 is that can promote vascular contraction,
regulating blood pressure and promoting aldosterone re-
lease [27]. Al-N et al. found that AGT rs2067853 rs699
rs3789679 rs2148582 rs5051 polymorphisms could in-
crease the risk for myocardial infarction [32].
Recently, people found that angiotensin II seemed to
have a key character in the development of NASH [7].
Table 1 Basic characteristics of this study population
Characteristics Groups P value
CAD+ NAFLD (n = 574) CAD- NAFLD (n = 589) NAFLD-CAD (n = 332) Controls (n = 338) P1 P2 P3 P4
Age (years) 43.81 ± 7.58 45.06 ± 8.77 46.45 ± 9.68 43.85 ± 8.79 0.996 0.921 0.884 0.912
Sex Female/male 292/282 301/288 168/164 173/165 0.927 0.981 0.880 0.934
Smoker, no. (%) 244 (42.5) 158 (26.8) 132 (39.6) 105 (31.3) <0.001 <0.001 0.019 <0.001
Hypertension, no. (%) 279 (48.6) 225 (38.2) 147 (44.3) 71 (21.2) <0.001 <0.001 <0.001 <0.001
ALT (U/L) 41.05 ± 8.50 40.69 ± 9.42 21.91 ± 5.90 19.15 ± 6.04 <0.001 <0.001 <0.001 0.487
AST (U/L) 42.67 ± 7.58 42.32 ± 8.12 22.11 ± 5.71 21.63 ± 5.82 <0.001 <0.001 0.035 0.451
GGT (U/L) 40.18 ± 8.42 40.08 ± 8.42 22.37 ± 5.35 19.43 ± 5.60 <0.001 <0.001 <0.001 0.839
TG (mmol/L) 2.49 ± 0.94 2.02 ± 0.82 1.41 ± 0.75 1.28 ± 0.70 <0.001 <0.001 0.027 <0.001
TC (mmol/L) 5.50 ± 1.01 4.72 ± 1.32 4.52 ± 1.22 4.04 ± 1.24 <0.001 <0.001 <0.001 <0.001
HDL (mmol/L) 1.10 ± 0.25 1.22 ± 0.31 1.34 ± 0.46 2.19 ± 0.64 <0.001 <0.001 <0.001 <0.001
LDL (mmol/L) 3.22 ± 0.62 2.96 ± 0.72 2.40 ± 0.57 2.54 ± 0.62 <0.001 <0.001 <0.001 <0.001
BMI (kg/m2) 26.88 ± 3.77 26.29 ± 4.03 26.18 ± 3.42 23.22 ± 2.69 <0.001 <0.001 <0.001 0.988
BMI body mass index, ALT alanine aminotransferase, AST aspartate aminotransferase, TG triglyceride, TC total cholesterol, HDL high-density lipoprotein, LDL
low-density lipoprotein. p1: CAD+ NAFLD vs. Control; p2: CAD-NAFLD vs. Control; p3: NAFLD-CAD vs. Control; p4: CAD+ NAFLD vs. CAD-NAFLD
Table 2 Distribution ofAGTR1 rs772622 polymorphisms in CAD-
NAFLD and control groups
Groups genotype alleles
T/T C/T C/C T C
control 115 (34) 155 (45.9) 68 (20.1) 385 (56.9) 291 (43.1)
CAD-NAFLD 161 (27.3) 301 (51.1) 127 (21.6) 623 (52.4) 555 (46.4)
χ2 4.64 2.86
p value 0.098 0.091
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They found that AngII acts on AGTR1 to activate hep-
atic stellate cells (HSCs), which could express the trans-
forming growth factor-β1 (TGF-β1). TGF-β1 worked as
a counter response to liver injury [33], While Z et al.
found that AGTR1 gene rs3772622 was not associated
with NAFLD and NASH [17]. This was in contrast with
the Japanese study. Our studies found that AGTR1 gene
rs3772622 was not associated with NAFLD in Chinese
Han. The cause of the difference between different pop-
ulations may be related to the factors such as race, envir-
onment and NAFLD diagnostic criteria. Angiotensin II
type1 (AT1) receptors were divided into AT1a and AT1b
two subtypes, and the distribution of subtype in liver
tissue was racial difference. The distribution of AT1 sub-
type in Chinese population has not clear yet.
The current study is the first report to report that
AGTR1 polymorphism increased the risk of NAFLD
patients suffering from CAD. In this study we demon-
strated that when compared with TC and TT genotype,
the CC homozygote and carriers of C allele was signifi-
cantly associated with NAFLD in patients with CAD, by
comparing the risk between NAFLD patients with or
without CAD, we found that there was a statistically
significant difference in patients with CC genotype. then
comparing the risk between without NAFLD people with
or without CAD, we found that there still had statisti-
cally significant difference in people with CC genotype.
However, by comparing the two OR values, AGTR1
rs3772622 polymorphisms can increase the risk of CAD
in patients with NAFLD (OR1 >OR2).
NAFLD and CAD are both metabolic diseases, and
study found that NAFLD is an independent risk factor
for CAD. There must be a mechanism for the inter-
action between them.
However, our current study still has several limitations
yet. We have the limitations on the studies of NAFLD
spectrum, as we all know that the gold standard to diag-
nose NAFLD is liver biopsy, it can valid ascertainment
and scoring of the different NAFLD stages. In clinical
diagnosis, only limited application can we use liver biopsy
technology. So it could not be widely used in the collec-
tion of specimens. Compared with the diagnosis of NASH,
diagnosis of NAFLD can be based on radiological, clinical,
and laboratory findings. Through these pathways above, it
was more easily to collect the specimens of NAFLD
patients. Ethics committee stipulated that it is not allow
for biopsy in control group, thus no biopsies were applyed
in controls. Strict criteria are required to reduce the likeli-
hood of misclassifying in control group.
This final conclusion is that AGTR1 rs3772622 gene
polymorphism was not associated with the risk of
NAFLD, but could increase the risk of NAFLD patients
suffering from CAD in the Chinese Han origin.
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